dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Moserle, Lidia |
dc.contributor.author | Pons, Roser |
dc.contributor.author | Martínez-Lozano, Mar |
dc.contributor.author | Jiménez-Valerio, Gabriela A |
dc.contributor.author | Vidal, August |
dc.contributor.author | Suárez Rodríguez, Cristina |
dc.contributor.author | Trilla Herrera, Enric |
dc.contributor.author | Jiménez Flores, José Antonio |
dc.contributor.author | Torres Ramirez, Inés de |
dc.contributor.author | Carles Galceran, Joan |
dc.date.accessioned | 2021-09-09T05:50:22Z |
dc.date.available | 2021-09-09T05:50:22Z |
dc.date.issued | 2020-12-07 |
dc.identifier.citation | Moserle L, Pons R, Martínez‐Lozano M, Jiménez‐Valerio GA, Vidal A, Suárez C, et al. Kidney cancer PDOXs reveal patient‐specific pro‐malignant effects of antiangiogenics and its molecular traits. EMBO Mol Med. 2020 Dec 7;12:e11889. |
dc.identifier.issn | 1757-4684 |
dc.identifier.uri | https://hdl.handle.net/11351/6279 |
dc.description | Antiangiogènica; Resistència al càncer; Inducció de metàstasi |
dc.description.sponsorship | This work was supported by research grants from ERC (ERC-StG-281830) EU-FP7, Ministerio de Ciencia, Innovación y Universidades, through the Retos Investigación grant, Refs: SAF2016-79347-R and PID2019-107557RB-I00/AEI/10.13039/501100011033, ISCIII Spain (AES, DTS17/00194), AGAUR-Generalitat de Catalunya (2017SGR771), Marató de TV3 (201910-30-31-32) and Italian Association for Cancer Research (AIRC) IG#14032, DOR - University of Padova, IOV 5x1000 fund. We thank CERCA Programme / Generalitat de Catalunya for institutional support. |
dc.language.iso | eng |
dc.publisher | Wiley |
dc.relation.ispartofseries | EMBO Molecular Medicine;12 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Ronyons - Càncer |
dc.subject | Angiogènesi - Inhibidors - Efectes secundaris |
dc.subject.mesh | Kidney Neoplasms |
dc.subject.mesh | Angiogenesis Inhibitors |
dc.subject.mesh | /adverse effects |
dc.title | Kidney cancer PDOXs reveal patient-specific pro-malignant effects of antiangiogenics and its molecular traits |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.15252/emmm.201911889 |
dc.subject.decs | neoplasias renales |
dc.subject.decs | inhibidores de la angiogénesis |
dc.subject.decs | /efectos adversos |
dc.relation.publishversion | https://doi.org/10.15252/emmm.201911889 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Moserle L, Pons R, Martínez-Lozano M, Jiménez-Valerio GA] Tumor Angiogenesis Group, ProCURE Program, Catalan Institute of Oncology, OncoBell Program, IDIBELL, Barcelona, Spain. [Vidal A] Tumor Angiogenesis Group, ProCURE Program, Catalan Institute of Oncology, OncoBell Program, IDIBELL, Barcelona, Spain. [Suárez C, Jiménez J, Carles J] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Trilla E] Servei de Cirurgia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Torres I] Servei de Patologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain |
dc.identifier.pmid | 33151035 |
dc.identifier.wos | 000586314700001 |
dc.relation.projectid | info:eu-repo/grantAgreement/EC/FP7/281830 |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2013-2016/SAF2016-79347-R |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2017-2020/PID2019-107557RB-I00 |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2013-2016/DTS17%2F00194 |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PERIS2016-2020/2017SGR771 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |